Literature DB >> 18695761

Analysis of mortality rates for pancreatic cancer across the world.

D Hariharan1, A Saied, H M Kocher.   

Abstract

INTRODUCTION: Pancreas cancer is the fourth commonest cause of cancer-related mortality across the world, with incidence equalling mortality. A recent study has suggested that both the incidence and the mortality of pancreatic cancer are falling in the UK. We investigated whether this trend was being seen all over the world.
METHODS: Age-standardized mortality (world) rates [ASR(W)] for pancreatic cancer were extracted separately for males and females from a database maintained by the International Agency for Research on Cancer for 51 countries across the world (Europe, 33 countries; Americas, 8 countries; and Asia, 10 countries) for the period 1992-2002; log-linear regression analysis was performed to analyse trends in the past decade.
RESULTS: In the period 1992-2002, the ASR(W) remained static across most countries for both sexes. The highest mortality rates (for both sexes) were seen in Central Europe [range: men (8-12), women (4.5-7)] with trends towards increasing mortality in Romania (p<0.001), along with Albania, Spain and Croatia (p<0.01). Korea in the Far East, too, demonstrated increasing mortality trends for both sexes (men p<0.001, women p<0.01). Increasing mortality trends were also observed among women in France (p<0.001). In Canada, there was a decline in mortality [men (7.5-6.4), women (5.9-5); p<0.01], while for men there was a downward trend in Ireland, the UK, Switzerland, Austria, and Poland [p<0.05].
CONCLUSION: The changes perhaps reflect standardization and consolidation of diagnostic tests for pancreatic cancer in the Western world and further in-depth analysis would be required.

Entities:  

Keywords:  Age standardized mortality; pancreatic cancer; trends

Year:  2008        PMID: 18695761      PMCID: PMC2504856          DOI: 10.1080/13651820701883148

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  15 in total

Review 1.  Cancer burden in the year 2000. The global picture.

Authors:  D M Parkin; F I Bray; S S Devesa
Journal:  Eur J Cancer       Date:  2001-10       Impact factor: 9.162

2.  Cigarette smoking and pancreas cancer: a case control study of the search programme of the IARC.

Authors:  P Boyle; P Maisonneuve; B Bueno de Mesquita; P Ghadirian; G R Howe; W Zatonski; P Baghurst; C J Moerman; A Simard; A B Miller; K Przewoniak; A J McMichael; C C Hsieh; A M Walker
Journal:  Int J Cancer       Date:  1996-07-03       Impact factor: 7.396

Review 3.  Current standards of surgery for pancreatic cancer.

Authors:  N Alexakis; C Halloran; M Raraty; P Ghaneh; R Sutton; J P Neoptolemos
Journal:  Br J Surg       Date:  2004-11       Impact factor: 6.939

4.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

Review 5.  Pancreatic cancer.

Authors:  Donghui Li; Keping Xie; Robert Wolff; James L Abbruzzese
Journal:  Lancet       Date:  2004-03-27       Impact factor: 79.321

Review 6.  Epidemiology and risk factors for pancreatic cancer.

Authors:  Albert B Lowenfels; Patrick Maisonneuve
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006-04       Impact factor: 3.043

7.  Pancreas cancer is unrelated to the workplace in Los Angeles.

Authors:  T M Mack; J M Peters; M C Yu; R Hanisch; W E Wright; B E Henderson
Journal:  Am J Ind Med       Date:  1985       Impact factor: 2.214

Review 8.  Epidemiology of pancreas cancer (1988).

Authors:  P Boyle; C C Hsieh; P Maisonneuve; C La Vecchia; G J Macfarlane; A M Walker; D Trichopoulos
Journal:  Int J Pancreatol       Date:  1989-12

9.  Mortality among California Seventh-Day Adventists for selected cancer sites.

Authors:  R L Phillips; L Garfinkel; J W Kuzma; W L Beeson; T Lotz; B Brin
Journal:  J Natl Cancer Inst       Date:  1980-11       Impact factor: 13.506

10.  Trends in stomach and pancreatic cancer incidence and mortality in England and Wales, 1951-2000.

Authors:  D Fitzsimmons; C Osmond; S George; C D Johnson
Journal:  Br J Surg       Date:  2007-09       Impact factor: 6.939

View more
  135 in total

1.  Reverse correlation of Jab1 and Smad4 in PANC-1 cells involved in the pathogenesis of pancreatic cancer.

Authors:  Jun Li; Zhuoyu Gu; Siyuan Li; Zhiwei Xiao; Kan Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 2.  Drug eluting biliary stents to decrease stent failure rates: A review of the literature.

Authors:  Joseph Shatzel; Jisoo Kim; Kartik Sampath; Sharjeel Syed; Jennifer Saad; Zilla H Hussain; Kabir Mody; J Marc Pipas; Stuart Gordon; Timothy Gardner; Richard I Rothstein
Journal:  World J Gastrointest Endosc       Date:  2016-01-25

3.  Identifying patients with undetected pancreatic cancer in primary care: an independent and external validation of QCancer(®) (Pancreas).

Authors:  Gary S Collins; Douglas G Altman
Journal:  Br J Gen Pract       Date:  2013-09       Impact factor: 5.386

4.  Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Authors:  Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

5.  Comparison of 22G reverse-beveled versus standard needle for endoscopic ultrasound-guided sampling of solid pancreatic lesions.

Authors:  Abdullah Alatawi; Frédéric Beuvon; Sophie Grabar; Sarah Leblanc; Stanislas Chaussade; Benoit Terris; Maximilien Barret; Frédéric Prat
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

6.  Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer.

Authors:  Mao-Song Lin; Wei-Chang Chen; Jun-Xing Huang; Heng-Jun Gao; Hai-Hui Sheng
Journal:  Int J Clin Exp Med       Date:  2014-12-15

7.  Trojan-horse nanotube on-command intracellular drug delivery.

Authors:  Chia-Hsuan Wu; Cong Cao; Jin Ho Kim; Chih-Hsun Hsu; Harold J Wanebo; Wayne D Bowen; Jimmy Xu; John Marshall
Journal:  Nano Lett       Date:  2012-10-25       Impact factor: 11.189

8.  Efficient Synthesis of ESI-09, A Novel Non-cyclic Nucleotide EPAC Antagonist.

Authors:  Haijun Chen; Chunyong Ding; Christopher Wild; Huiling Liu; Tianzhi Wang; Mark A White; Xiaodong Cheng; Jia Zhou
Journal:  Tetrahedron Lett       Date:  2013-03-20       Impact factor: 2.415

9.  Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells.

Authors:  Fieke E M Froeling; Tariq A Mirza; Roger M Feakins; Angela Seedhar; George Elia; Ian R Hart; Hemant M Kocher
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

10.  CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy.

Authors:  Michael Jermyn; Scott C Davis; Hamid Dehghani; Matthew T Huggett; Tayyaba Hasan; Stephen P Pereira; Stephen G Bown; Brian W Pogue
Journal:  Phys Med Biol       Date:  2014-03-20       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.